MONISTAT 7 (miconazole nitrate) by Design Pharmaceuticals is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1974.
Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
MONISTAT 7 (miconazole nitrate) is a vaginal cream antifungal indicated for vulvovaginal candidiasis. The drug exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. It is administered intravaginally with minimal systemic absorption.
Mature product approaching loss of exclusivity with likely modest team size focused on brand defense and generic transition planning.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 7 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MONISTAT 7 offers limited career growth given its mature, generic-threatened lifecycle stage and lack of active job opportunities. Roles are primarily commercial and defensive in nature, focused on market share protection rather than innovation or expansion.